GLP-1 Side Effects for Weight Loss: What to Expect and When to Get Help

GLP-1 weight-loss medications most often cause digestive side effects, including nausea, vomiting, diarrhea, constipation, and stomach discomfort. Symptoms are often most noticeable after starting or changing treatment. Less common problems, such as severe abdominal pain, dehydration, or low blood sugar with certain diabetes medicines, need prompt clinical review.1 2

What side effects can GLP-1 medications cause for weight loss?

GLP-1 receptor agonists are medicines that act like glucagon-like peptide-1, or GLP-1. The most common effects are digestive: nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. They are often more noticeable in the first few weeks or after a treatment change.1 2

Semaglutide is a GLP-1 receptor agonist sold in FDA-approved products including Ozempic and Wegovy. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist sold in FDA-approved products including Mounjaro and Zepbound. Liraglutide, sold as Saxenda for weight management, is another GLP-1 receptor agonist.1 2 5

The most common side effects at a glance

Why do GLP-1 medications often cause nausea and other digestive symptoms?

GLP-1 medicines affect signals between the gut, pancreas, and brain. They can increase fullness, reduce food intake, and slow stomach emptying; these actions help explain why nausea, early fullness, and other gastrointestinal symptoms can occur, especially during the early adjustment period.6 1

How GLP-1 receptor agonists affect appetite, digestion, and blood sugar

GLP-1 signaling helps the body release insulin when glucose is elevated and can reduce appetite. In a small randomized human study, GLP-1 plus glucagon reduced food intake, supporting the role of these gut-hormone signals in eating behavior.6 The same biology can make large meals, rich foods, or low fluid intake feel harder to tolerate for some people, although each person's experience differs.

Why symptoms can vary by medicine, dose, and person

Side effects differ by medication, formulation, dose exposure, other medicines, medical history, and how quickly treatment changes. In randomized trials of semaglutide and tirzepatide for weight management, gastrointestinal events were common, but many participants were able to continue treatment with study-guided monitoring.3 4 A clinician should review prior stomach-emptying problems, gallbladder history, kidney disease, diabetes medicines, and pregnancy plans before treatment.

Which GLP-1 side effects are common?

Nausea and constipation are among the most frequently reported concerns with GLP-1-based weight-management medicines. In clinical trials, these effects were usually mild to moderate, but they can still be disruptive and sometimes lead people to stop treatment. Symptoms should be discussed early rather than ignored for several days.1 2 3

Nausea, vomiting, diarrhea, constipation, and abdominal discomfort

FDA labeling for semaglutide and tirzepatide products lists nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion among common adverse reactions.1 2 Repeated vomiting or diarrhea can lead to dehydration, which may worsen kidney problems in susceptible people.1 2

Reduced appetite and fatigue

Lower appetite is part of how these medicines may support weight management, but it can become a problem if food and fluid intake fall too far. Fatigue is not specific to GLP-1 treatment and can have many causes, including reduced intake, dehydration, poor sleep, illness, or rapid weight loss. A clinician can help sort out what is happening rather than assuming the medication is the only cause.3

Injection-site reactions with injectable medicines

Injection-site reactions can occur with injectable semaglutide or tirzepatide products and may include redness, itching, or localized discomfort.1 2 A person with swelling of the face or throat, trouble breathing, fainting, or widespread hives should seek emergency care because these can be signs of a serious allergic reaction.1 2

Which symptoms need urgent medical attention?

Severe abdominal pain and ongoing vomiting are not symptoms to simply wait out. Call a clinician promptly for severe, persistent, or worsening symptoms, and seek emergency care for symptoms that feel like an emergency. Product labels describe serious risks that require attention, even though they are less common than digestive side effects.1 2

Severe or persistent abdominal pain, repeated vomiting, or dehydration

Severe stomach pain that may spread to the back, especially with vomiting, needs urgent evaluation for pancreatitis or another abdominal condition. Repeated vomiting, inability to keep fluids down, dizziness, fainting, or markedly reduced urination can signal dehydration and deserve timely care.1 2

Symptoms that may need evaluation for gallbladder, pancreas, kidney, or stomach-emptying problems

GLP-1 product labels warn about pancreatitis, gallbladder disease, acute kidney injury related to volume depletion, and severe gastrointestinal reactions.1 2 Right-upper abdominal pain, fever, yellowing skin or eyes, persistent severe pain, or worsening dehydration are reasons to contact a clinician promptly. People with severe stomach-emptying disorders need individualized assessment because these medicines delay gastric emptying.1 2

Low blood sugar risk when GLP-1 medicines are used with certain diabetes medicines

GLP-1 medicines alone generally have a lower hypoglycemia risk than medicines that directly raise insulin regardless of glucose level. The risk can increase when a GLP-1 medicine is combined with insulin or a sulfonylurea, so the prescribing clinician may need to review the full diabetes regimen.1 2 Symptoms such as shaking, sweating, confusion, or unusual weakness need prompt attention.

Can GLP-1 weight loss affect your face, hair, skin, or muscle?

Rapid weight loss can change facial volume, hair growth cycles, and body composition, whether weight loss occurs with medication, surgery, illness, or major dietary change. “GLP-1 face” is not a medical diagnosis or a formal medication-specific adverse effect. The key timeframe is often months of weight change, not one dose or one week.9

Why GLP-1 face is not a formal diagnosis or medication-specific adverse effect

Facial changes generally reflect loss of fat beneath the skin, which can make lines or loose skin more noticeable. This may happen with substantial weight loss from many causes. It is not established as a direct toxic effect of semaglutide, tirzepatide, or another GLP-1 medicine.9

Hair shedding and body-composition changes: what is known and what remains uncertain

Temporary hair shedding can follow physical stress, rapid weight loss, or inadequate protein and nutrient intake. It is important not to assume that a GLP-1 is the sole cause, because thyroid disease, iron deficiency, hormonal changes, and other conditions can also contribute.9 Weight loss can include both fat mass and lean mass, which is one reason nutrition and resistance exercise discussions matter during a clinician-guided plan.3 4

What do we know about long-term GLP-1 safety?

Long-term safety is studied through clinical trials, FDA-required labeling, and post-marketing reports. These sources can identify common patterns and some rare risks, but no study can answer every question for every person over a lifetime. Safety depends on the specific medicine, the person using it, and their other conditions and medicines.1 2

What longer clinical trials and post-marketing monitoring can and cannot tell us

A two-year randomized trial of liraglutide reported sustained weight loss and collected ongoing safety and tolerability data, illustrating why longer follow-up matters.5 Larger semaglutide and tirzepatide weight-management trials also reported gastrointestinal events as the most frequent adverse events.3 4 Post-marketing reporting can raise safety signals, but it cannot by itself prove that a medicine caused an event.

Ozempic, Wegovy, Mounjaro, and Zepbound: why approved use and safety information differ

Ozempic and Wegovy contain semaglutide, while Mounjaro and Zepbound contain tirzepatide, but their FDA-approved uses and labeling are not identical. A clinician should use the label and medical history that apply to the particular product and indication rather than treating all “GLP-1s” as interchangeable.1 2 Labels also list a contraindication for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.1 2

Suicidal thoughts and behavior: what the FDA review found

In 2026, the FDA concluded that available evidence did not support a causal relationship between GLP-1 receptor agonists and suicidal thoughts or behavior. Its review included a meta-analysis of 91 trials involving 107,910 participants and a large observational comparison from the FDA Sentinel System.8 Mental-health symptoms still deserve timely clinical attention, regardless of the suspected cause.

How can patients discuss side effects safely with a clinician?

Clinician-guided treatment gives you a way to weigh expected digestive symptoms against your health history and goals. Before the first prescription, share your full medication list, diabetes treatment, prior pancreas or gallbladder problems, kidney history, severe digestive symptoms, and pregnancy plans.1 2

What to report before starting treatment

Tell the clinician about prior pancreatitis, gallbladder disease, kidney disease, severe gastrointestinal disease, low blood sugar episodes, and a personal or family history of medullary thyroid carcinoma or MEN2. Also report insulin, sulfonylureas, and other prescription medicines so interaction and hypoglycemia risks can be reviewed.1 2

Why treatment changes should be clinician-guided

Do not make dose or treatment changes based on social-media advice or another person's experience. Your prescriber can assess whether symptoms call for monitoring, a treatment adjustment, evaluation for another cause, or urgent care. For practical food and fluid planning, see our guide to what to eat on GLP-1 medication and our broader GLP-1 side-effects guide.

What happens if you stop a GLP-1 medication after losing weight?

Weight regain can occur after stopping GLP-1 treatment because appetite and metabolic pressures do not disappear when medication ends. In the STEP 1 extension, participants regained weight during the one-year period after semaglutide withdrawal, although individual experiences varied.7

Appetite and weight regain can occur after treatment stops

The STEP 1 extension studied semaglutide withdrawal after a 68-week trial and found that participants regained a substantial portion of prior weight loss over the following year.7 This is a study result, not a prediction for any one person. It supports planning for continued nutrition, activity, and clinical support if treatment is changed or stopped.

Planning ongoing weight-management support

A sustainable plan considers medication tolerance, nutrition, sleep, movement, stress, medical conditions, and follow-up. A clinician can help decide whether continuing, pausing, or changing a treatment is appropriate. Our overview of side effects of weight-loss drugs covers additional questions to bring to that conversation.

How does GLP-1 treatment at Chia work?

At Chia, compounded semaglutide and tirzepatide are available only after a licensed US provider reviews your health information and determines that treatment is clinically appropriate. Care is 100% online: you complete a short questionnaire, a provider reviews it, and prescriptions are never guaranteed.

We offer compounded semaglutide by injection, and compounded tirzepatide as tablets or injections. Both have provider-guided microdosing plans available. Medications are compounded in the US by state-licensed 503A compounding pharmacies, shipped to your door, and supported with patient-portal messaging between visits. Compounded formulations are not FDA-approved, and results are not established by FDA-evaluated outcomes data for compounded formulations.

A provider can review whether a GLP-1-based option fits your history, current medicines, symptoms, and goals. If you are comparing active ingredients, our guide to which GLP-1 may be best for weight loss explains how semaglutide and tirzepatide differ in the clinical evidence.

Keep reading

Weight Management

Best Diabetes Drugs for Weight Loss: Semaglutide, Tirzepatide, and Metformin Compared

Weight Management

Online GLP-1 Programs: How They Work, What They Cost, and How to Choose Safely

Weight Management

GLP-1 Injection Side Effects: What’s Common, Serious, and Worth Discussing